SEHK:6996Pharmaceuticals
Antengene (SEHK:6996) Losses Halve In 1H 2025 Challenging Concerns Over Rich P/S Multiple
Antengene (SEHK:6996) has opened FY 2025 with first half revenue of C¥53.2 million and a basic EPS loss of C¥0.12 per share, setting the tone for how investors will assess its path toward profitability. Over the past few reporting periods, the company has seen revenue move from C¥60.8 million in 1H 2024 to C¥31.2 million in 2H 2024 and C¥53.2 million in 1H 2025, while basic EPS has shifted from a loss of C¥0.27 to a loss of C¥0.24 and then to a loss of C¥0.12. With revenue still modest and...